Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Mirum Pharmaceuticals president and COO Peter Radovich reported a combination of equity award vesting and share sales. He exercised performance restricted stock units into 30,220 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings.
On the following day, he sold 16,515 common shares at an average price of $91.9779 per share, with a footnote stating the sale was to cover tax withholding obligations from the RSU vesting. After these transactions, he directly holds 40,272 common shares and continues to hold 11,500 performance restricted stock units scheduled to vest over future dates.
Mirum Pharmaceuticals, Inc. senior vice president and global controller Jolanda Howe exercised performance restricted stock units into 8,658 shares of common stock, each unit representing one share. On March 16, 2026, she sold 4,732 common shares at 91.9779 per share to cover tax withholding obligations related to this vesting, and held 8,429 shares afterward. Footnotes state the performance restricted stock units vest in stages over March 15, 2025–2027.
Mirum Pharmaceuticals CEO Christopher Peetz reported a mix of stock exercises and a tax-related sale. On March 15, 2026, he exercised performance restricted stock units covering 75,000 shares of common stock at a conversion price of $0.00, increasing his direct holdings.
On March 16, 2026, Peetz executed an open-market sale of 40,985 shares of common stock at an average price of $91.9779 per share. A footnote states these shares were sold to cover tax withholding obligations tied to the vesting of the performance restricted stock units, indicating a mechanistic, tax-driven transaction rather than a discretionary sale. After these transactions, he directly held 194,309 shares, with an additional 187,500 shares held indirectly by The Peetz Family Trust.
Mirum Pharmaceuticals submitted a Form 144 notice to sell 7,287 shares of Common Stock, tied to Restricted Stock Units vesting under a registered plan. The filing lists the proposed disposition by an issuer-related broker on 03/15/2026.
The filing also discloses two recent sales by Eric Bjerkholt: 1,421 shares sold on 01/22/2026 for $132,615.15 and 1,053 shares sold on 01/26/2026 for $101,290.18. The notice records the broker as Morgan Stanley Smith Barney LLC.
Joanne Quan reports proposed sale of 7,287 shares of Mirum Pharmaceuticals common stock. The Form 144 lists 7,287 shares tied to restricted stock units vesting under a registered plan and names Morgan Stanley Smith Barney LLC as broker, dated 03/16/2026. The filing also discloses prior dispositions of 6,911 shares on 01/20/2026 for $623,853.21 and 1,822 shares on 01/22/2026 for $170,038.51.
Mirum Pharmaceuticals notice of proposed sale: the filing reports a proposed sale of 16,515 shares of Common Stock, with an aggregate amount shown as $1,529,949.60, dated 03/16/2026. The filing states the securities are Restricted Stock Units vesting under a registered plan on 03/15/2026.
The filing also lists prior open-market sales by Peter Radovich of 2,382, 3,143 and 2,631 shares on 01/22/2026, 01/26/2026 and 02/02/2026, respectively, with corresponding aggregate values shown.
Mirum Pharmaceuticals submitted a Form 144 notice reporting proposed sales of Common Stock tied to Restricted Stock Units vesting under a registered plan. The filing lists a broker Morgan Stanley Smith Barney LLC and shows recent dispositions by a holder, including multiple small share sales in January–February 2026.
Mirum Pharmaceuticals reported reported transactions of Common Stock under Form 144 by Christopher Peetz. The filing lists three dispositions: 7,098 shares on 01/22/2026, 6,831 shares on 01/26/2026, and 9,108 shares on 02/02/2026. The shares are described as Restricted Stock Units vesting under registered plan, issued as compensation for services.
Saira Ramasastry reported a proposed sale of Common Stock. The notice covers 2,000 shares to be sold on 03/16/2026 pursuant to a stock option exercise for cash, listed as "ISSUER" in the filing.
The filing also lists recent dispositions by the same holder: 2,000 shares on 02/13/2026 for $204,180.00, 2,000 shares on 01/15/2026 for $181,980.00, 5,000 shares on 12/22/2025 for $400,000.00, and 2,000 shares on 12/18/2025 for $139,460.00.
Mirum Pharmaceuticals president and COO Peter Radovich exercised stock options to acquire 5,912 shares of common stock at an exercise price of $15.87 per share. These options were fully vested. Following the transaction, he directly owns 26,567 shares of common stock and holds 54,088 stock options.
No shares were sold and no tax-withholding dispositions were reported, making this a straightforward exercise-and-hold transaction that increases his direct equity stake in the company.